Seizures

2 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Seizures has 2 FDA-approved novel treatments, led by JAZZ PHARMS RES across 5 drug targets. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Seizures Market Leaders

Companies with the most FDA-approved novel Seizures drugs.

Phase 3 Readouts Pro

12 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q3 2026

Brivaracetam

UCB Biopharma SRL

Estimated · fresh NCT04666610

Q3 2026

Cenobamate

SK Life Science, Inc.

Estimated · fresh NCT03961568

Q4 2026

XEN1101

Xenon Pharmaceuticals Inc.

Estimated · fresh NCT05716100

Unlock 9 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Seizures Treatments by Mechanism

Top 12 mechanisms across 97 industry trials with a known mechanism of action.

See full pipeline →

Epoxide Hydrolase Inhibitors [MoA]

17 trials 2 active 6 sponsors

Sodium Channel Antagonists [MoA]

5 trials 2 active 2 sponsors

5-HT2 receptor

1 trials 1 active 1 sponsor

Voltage-gated sodium channels

28 trials 9 sponsors

Anti-epileptic Agent

14 trials 6 sponsors

SV2A

11 trials 7 sponsors

Noncompetitive AMPA Glutamate Receptor Antagonist

10 trials 3 sponsors

alpha 2 ‑delta subunit of voltage‑gated calcium channels

3 trials 1 sponsor

Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

3 trials 1 sponsor

Cytochrome P450 3A4 Inducers [MoA]

2 trials 1 sponsor

Benzodiazepine

2 trials 2 sponsors

Integrin Receptor Antagonist

1 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Seizures Clinical Pipeline by Phase

297 industry-sponsored trials across 83 sponsors

Showing 19 of 19 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Azurity Pharmaceuticals	Zonisamide Oral Product	—	NOT YET RECRUITING	2027-09	NCT06534502
Eisai Korea Inc.	Perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2025-01-23	NCT05533814
Eisai Inc.	Perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2021-04-27	NCT03288129
Sumitomo Pharma America, Inc.	Eslicarbazepine acetate	Voltage-gated sodium channels	COMPLETED	2019-06-06	NCT03116828
Hamad Medical Corporation	Buccal midazolam	—	COMPLETED	2018-11	NCT02897856
Eisai Korea Inc.	Perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2018-04-26	NCT02726074
GSK	Lamotrigine tablets 25/100 mg	—	COMPLETED	2015-05-11	NCT02100644
UCB Korea Co., Ltd.	Levetiracetam	SV2A	COMPLETED	2015-05	NCT01229735
Korea UCB Co., Ltd.	Levetiracetam	SV2A	COMPLETED	2014-07	NCT01498822
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Pregabalin	alpha 2 ‑delta subunit of voltage‑gated calcium channels	COMPLETED	2013-07	NCT00537940
Johnson & Johnson Taiwan Ltd	Topiramate add-on therapy	—	COMPLETED	2011-01	NCT01627860
Eisai Korea Inc.	zonisamide	Anti-epileptic Agent [EPC]	COMPLETED	2010-08-31	NCT01140867
Johnson & Johnson	Topiramate	Cytochrome P450 3A4 Inducers [MoA]	COMPLETED	2010-01-19	NCT01689649
Eisai Inc.	Zonisamide	Anti-epileptic Agent [EPC]	COMPLETED	2009-09	NCT00659958
Eisai Limited	Zonisamide	Anti-epileptic Agent [EPC]	COMPLETED	2008-12	NCT00713622
GSK	ezogabine/retigabine	—	TERMINATED	2016-11-16	NCT01607346
GSK	Ezogabine/Retigabine IR	—	TERMINATED	2013-06-20	NCT01721317
Eisai Limited	Zonisamide at targeted daily doses of 100-500 mg/day	—	TERMINATED	2010-11	NCT01546688
Eisai Inc.	Perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	WITHDRAWN	2016-08	NCT02220972

Showing 100 of 128 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
UCB Biopharma SRL	Staccato alprazolam	—	RECRUITING	2026-06-30	NCT05077904
Xenon Pharmaceuticals Inc.	XEN1101	—	RECRUITING	2026-10	NCT05716100
Biohaven Therapeutics Ltd.	BHV-7000	—	RECRUITING	2026-12	NCT06132893
Praxis Precision Medicines	40 mg/day vormatrogine for 12 weeks	—	RECRUITING	2027-01	NCT07505004
Ono Pharmaceutical Co., Ltd.	Cenobamate	Sodium Channel Antagonists [MoA]	RECRUITING	2027-01-31	NCT06579573
SK Life Science, Inc.	Carisbamate	—	RECRUITING	2027-02	NCT05219617
Ono Pharmaceutical Co., Ltd.	Cenobamate (tablet) for 12 to < 18 year olds	—	RECRUITING	2028-03-30	NCT07594158
Neurona Therapeutics	NRTX-1001	—	RECRUITING	2029-02	NCT05135091
Rapport Therapeutics Inc.	RAP-219	—	RECRUITING	2029-07	NCT07563881
Rapport Therapeutics Inc.	RAP-219	—	RECRUITING	2029-07	NCT07594119
UCB Biopharma SRL	Brivaracetam Film-coated tablet	—	RECRUITING	2030-03-01	NCT06315322
UCB Biopharma SRL	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	RECRUITING	2030-07-08	NCT04715646
Biohaven Therapeutics Ltd.	BHV-7000	—	RECRUITING	2026-05	NCT06309966
UCB Biopharma SRL	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	ACTIVE NOT RECRUITING	2026-08-24	NCT04666610
SK Life Science, Inc.	Xcopri	Sodium Channel Antagonists [MoA]	ACTIVE NOT RECRUITING	2026-11	NCT05067634
Zogenix, Inc.	Fenfluramine	5-HT2 receptor	ACTIVE NOT RECRUITING	2027-11-08	NCT05064878
NeuroPace	—	—	ACTIVE NOT RECRUITING	2025-04-04	NCT05147571
Xenon Pharmaceuticals Inc.	XEN1101	—	COMPLETED	2026-01-12	NCT05614063
SK Life Science, Inc.	Cenobamate	Sodium Channel Antagonists [MoA]	COMPLETED	2025-05-26	NCT03678753
UCB Biopharma SRL	Brivaracetam Film-coated tablet	—	COMPLETED	2025-03-18	NCT05109234
UCB Biopharma SRL	Lacosamide	Voltage-gated sodium channels	COMPLETED	2025-02-12	NCT04627285
UCB Biopharma SRL	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2024-12-24	NCT03250377
Jiangxi Qingfeng Pharmaceutical Co. Ltd.	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2024-05-21	NCT07563634
UCB BIOSCIENCES, Inc.	Lacosamide Tablet	—	COMPLETED	2023-03-30	NCT02408549
UCB Biopharma SRL	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2022-06-30	NCT03083665
UCB BIOSCIENCES, Inc.	Lacosamide	Voltage-gated sodium channels	COMPLETED	2022-04-13	NCT01964560
UCB Pharma SA	Brivaracetam (BRV)	—	COMPLETED	2022-02-03	NCT01364597
Jazz Pharmaceuticals	GWP42003-P	—	COMPLETED	2021-06-11	NCT02544750
SK Life Science, Inc.	YKP3089	—	COMPLETED	2021-03-31	NCT02535091
UCB Biopharma S.P.R.L.	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2021-03-27	NCT03685630
GW Research Ltd	GWP42003-P	—	COMPLETED	2020-09-24	NCT02224573
Aquestive Therapeutics	Diazepam Buccal Soluble Film 5, 7.5,10, 12.5,15 or 17.5 mg with individual dose determined according to age and weight category	—	COMPLETED	2020-06-25	NCT03428360
Neurelis, Inc.	NRL-1	—	COMPLETED	2020-06-17	NCT02721069
UCB BIOSCIENCES, Inc.	Lacosamide	Voltage-gated sodium channels	COMPLETED	2020-05-28	NCT02477839
Johnson & Johnson	Topiramate	Cytochrome P450 3A4 Inducers [MoA]	COMPLETED	2020-04-30	NCT02201251
UCB Biopharma S.P.R.L.	Lacosamide	Voltage-gated sodium channels	COMPLETED	2020-01	NCT02582866
Nobelpharma	Oxcarbazepine	Anti-epileptic Agent [EPC]	COMPLETED	2019-09-30	NCT01051193
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Pregabalin	alpha 2 ‑delta subunit of voltage‑gated calcium channels	COMPLETED	2019-08-22	NCT01463306
UCB Pharma SA	Lacosamide	Voltage-gated sodium channels	COMPLETED	2019-07-31	NCT01832038
UCB BIOSCIENCES, Inc.	Lacosamide	Voltage-gated sodium channels	COMPLETED	2019-06-28	NCT02710890
UCB BIOSCIENCES, Inc.	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2019-04-18	NCT01339559
UCB BIOSCIENCES, Inc.	Lacosamide Tablet	—	COMPLETED	2019-04	NCT02408523
Eisai Co., Ltd.	E2007	—	COMPLETED	2019-02-28	NCT03201900
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Pregabalin Dose Level 1	—	COMPLETED	2019-02-20	NCT01747915
Jazz Pharmaceuticals	GWP42003-P	—	COMPLETED	2019-01-22	NCT02544763
Bial - Portela C S.A.	ESL 800 mg	—	COMPLETED	2018-09-11	NCT02484001
Jazz Pharmaceuticals	GWP42003-P	—	COMPLETED	2018-04-09	NCT02224703
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Pregabalin Dose Level 1	—	COMPLETED	2018-03-13	NCT02072824
UCB Japan Co. Ltd.	Lacosamide	Voltage-gated sodium channels	COMPLETED	2017-11-21	NCT02124564
Novartis	RAD001	—	COMPLETED	2017-10-25	NCT01713946
INSYS Therapeutics Inc	Cannabidiol Oral Solution	—	COMPLETED	2017-06-22	NCT02318602
Sumitomo Pharma America, Inc.	Eslicarbazepine acetate	Voltage-gated sodium channels	COMPLETED	2017-04-15	NCT00910247
UCB Pharma	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2017-03	NCT00761774
UCB Pharma	Lacosamide	Voltage-gated sodium channels	COMPLETED	2017-01-24	NCT01921205
UCB BIOSCIENCES GmbH	Lacosamide	Voltage-gated sodium channels	COMPLETED	2017-01	NCT01465997
GSK	Retigabine IR	—	COMPLETED	2016-12-14	NCT01336621
GSK	Retigabine IR	—	COMPLETED	2016-12-14	NCT01777139
Eisai Co., Ltd.	Perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2016-09-21	NCT02427607
Bial - Portela C S.A.	Eslicarbazepine acetate (BIA 2-093)	—	COMPLETED	2016-09	NCT01162460
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Pregabalin add-on therapy	—	COMPLETED	2016-08-10	NCT01389596
UCB Pharma SA	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2016-08	NCT01728077
Jazz Pharmaceuticals	GWP42003-P	—	COMPLETED	2016-05-19	NCT02224560
UCB Pharma	Levetiracetam	SV2A	COMPLETED	2016-04	NCT01398956
Jazz Pharmaceuticals	GWP42003-P 20 mg/kg/day Dose	—	COMPLETED	2016-03-18	NCT02224690
Jazz Pharmaceuticals	GWP42003-P 20 mg/kg/day Dose	—	COMPLETED	2015-11-26	NCT02091375
UCB Pharma SA	Levetiracetam	SV2A	COMPLETED	2015-09	NCT01954121
UCB Biopharma S.P.R.L.	USL261	—	COMPLETED	2015-08	NCT01999777
UCB BIOSCIENCES GmbH	Lacosamide	Voltage-gated sodium channels	COMPLETED	2015-07	NCT01243177
Ache Laboratorios Farmaceuticos S.A.	Levetiracetam	SV2A	COMPLETED	2015-07	NCT01392768
UCB Pharma	Lacosamide	Voltage-gated sodium channels	COMPLETED	2014-12	NCT00530855
UCB Japan Co. Ltd.	Lacosamide (200 mg/20 mL)	—	COMPLETED	2014-10	NCT02192814
Eisai Inc.	perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2014-09	NCT00735397
UCB Pharma SA	Lacosamide 50 mg	—	COMPLETED	2014-07	NCT01710657
UCB Pharma	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2014-05	NCT01261325
Upsher-Smith Laboratories	USL255	—	COMPLETED	2014-05	NCT01191086
UCB Japan Co. Ltd.	Levetiracetam	SV2A	COMPLETED	2014-04	NCT01228747
GSK	Lamictal	Anti-epileptic Agent [EPC]	COMPLETED	2014-02	NCT01431976
UCB Pharma	Lacosamide	Voltage-gated sodium channels	COMPLETED	2013-12	NCT01484977
UCB Pharma SA	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2013-11	NCT01653262
Valexfarm	Remegal	—	COMPLETED	2013-10	NCT01749046
UCB Japan Co. Ltd.	Levetiracetam (LEV)	—	COMPLETED	2013-10	NCT01506882
Bial - Portela C S.A.	Eslicarbazepine Acetate	Voltage-gated sodium channels	COMPLETED	2013-09	NCT01422720
UCB Japan Co. Ltd.	Levetiracetam	SV2A	COMPLETED	2013-06	NCT01292837
Sumitomo Pharma America, Inc.	Eslicarbazepine acetate	Voltage-gated sodium channels	COMPLETED	2013-05	NCT00866775
GSK	Lamictal	Anti-epileptic Agent [EPC]	COMPLETED	2013-03	NCT01431963
Lundbeck LLC	Intravenous Carbamazepine (IV CBZ)	—	COMPLETED	2013-01	NCT01128959
West-Ward Pharmaceutical	Phenobarbital	—	COMPLETED	2013-01	NCT01284556
GSK	Retigabine IR	—	COMPLETED	2012-12	NCT01227902
Upsher-Smith Laboratories	USL255	—	COMPLETED	2012-12	NCT01142193
Sumitomo Pharma America, Inc.	Eslicarbazepine acetate 1600 mg	—	COMPLETED	2012-11	NCT01091662
Novartis	TRI476	—	COMPLETED	2012-10	NCT00975715
UCB Pharma	Brivaracetam tablets	—	COMPLETED	2012-07	NCT01405508
Bial - Portela C S.A.	800 mg QD Eslicarbazepine acetate	—	COMPLETED	2012-01-12	NCT00988429
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	pregabalin	alpha 2 ‑delta subunit of voltage‑gated calcium channels	COMPLETED	2011-12	NCT00596466
Supernus Pharmaceuticals, Inc.	Oxcarbazepine XR	—	COMPLETED	2011-11	NCT00908349
Eisai Inc.	Zonisamide	Anti-epileptic Agent [EPC]	COMPLETED	2011-06	NCT00848549
UCB Japan Co. Ltd.	Levetiracetam	SV2A	COMPLETED	2011-04	NCT01063764
Eisai Inc.	Zonisamide	Anti-epileptic Agent [EPC]	COMPLETED	2011-03	NCT00566254
SK Life Science, Inc.	carisbamate	—	COMPLETED	2010-08	NCT00744731
UCB BIOSCIENCES, Inc.	lacosamide	Voltage-gated sodium channels	COMPLETED	2010-06	NCT00655486

Showing 98 of 98 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
NeuroPro Therapeutics, Inc.	NPT 2042	—	RECRUITING	2026-08-30	NCT06769659
UniQure Biopharma B.V.	—	—	RECRUITING	2026-11-30	NCT06063850
NaviFUS Corporation	—	—	RECRUITING	2026-12-31	NCT06388707
Actio Biosciences, Inc.	ABS-1230	—	RECRUITING	2027-01	NCT07600736
Neurona Therapeutics	NRTX-1001	—	RECRUITING	2027-06-15	NCT06422923
Supernus Pharmaceuticals, Inc.	SPN-817	—	RECRUITING	2027-08	NCT06798896
Supernus Pharmaceuticals, Inc.	SPN-817	—	RECRUITING	2027-12-31	NCT05518578
Supernus Pharmaceuticals, Inc.	SPN-817	—	RECRUITING	2027-12-31	NCT07141329
Rapport Therapeutics Inc.	RAP-219	—	RECRUITING	2028-02-03	NCT07219407
Shanghai Zhimeng Biopharma, Inc.	CB03-154	—	RECRUITING	2029-01	NCT07238868
Bright Minds Biosciences Pty Ltd	BMB-101	—	RECRUITING	2025-09-15	NCT06401538
Praxis Precision Medicines	PRAX-222 - Initial Dose	—	RECRUITING	2025-08	NCT05737784
Praxis Precision Medicines	30mg PRAX-628	—	RECRUITING	2025-07	NCT06908356
Supernus Pharmaceuticals, Inc.	BIS-001ER	—	ACTIVE NOT RECRUITING	2026-12-30	NCT03474770
NeuroPace	—	—	ACTIVE NOT RECRUITING	2026-05-31	NCT05339126
Xenon Pharmaceuticals Inc.	XEN1101	—	ACTIVE NOT RECRUITING	2021-09-02	NCT03796962
Shanghai Zhimeng Biopharma, Inc.	Test drug CB03-154 5mg group	—	NOT YET RECRUITING	2026-08	NCT06612775
Rapport Therapeutics Inc.	RAP-219	—	COMPLETED	2025-09-26	NCT06377930
Neurelis, Inc.	Diazepam Nasal Spray [Valtoco]	—	COMPLETED	2025-03-11	NCT05076838
AbbVie	CVL-865	—	COMPLETED	2024-05-21	NCT04244175
Johnson & Johnson	JNJ-40411813	—	COMPLETED	2024-02-08	NCT04836559
Bial - Portela C S.A.	ESL 800 mg	—	COMPLETED	2023-09-11	NCT06597084
Neurocrine Biosciences	NBI-921352	—	COMPLETED	2023-08-21	NCT05159908
Eisai Inc.	perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2022-08-23	NCT02914314
Cerebral Therapeutics LLC	Valproate	—	COMPLETED	2021-06-01	NCT02899611
UCB BIOSCIENCES, Inc.	Lacosamide	Voltage-gated sodium channels	COMPLETED	2021-05-18	NCT00938912
SK Life Science, Inc.	YKP3089	—	COMPLETED	2021-04-05	NCT01866111
Marinus Pharmaceuticals	Ganaxolone	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	COMPLETED	2021-01-19	NCT03865732
UCB Biopharma S.P.R.L.	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2020-11-04	NCT03405714
Takeda	TAK-935	—	COMPLETED	2020-06-09	NCT03650452
UCB Biopharma S.P.R.L.	Padsevonil	—	COMPLETED	2020-01-30	NCT03373383
Aquestive Therapeutics	Diazepam Buccal Film	—	COMPLETED	2020-01-28	NCT03222349
Biogen	Natalizumab	Integrin Receptor Antagonist [EPC]	COMPLETED	2020-01-11	NCT03283371
Engage Therapeutics, Inc.	Staccato Alprazolam	—	COMPLETED	2019-12-22	NCT03478982
Eisai Co., Ltd.	Perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2019-12-10	NCT03754582
Marinus Pharmaceuticals	IV Ganaxolone active	—	COMPLETED	2019-09-18	NCT03350035
Aquestive Therapeutics	Diazepam Buccal Film	—	COMPLETED	2019-07-31	NCT03953820
Jazz Pharmaceuticals	GWP42003-P	—	COMPLETED	2019-05-27	NCT02607904
Jazz Pharmaceuticals	CX-8998	—	COMPLETED	2019-03-29	NCT03406702
Jazz Pharmaceuticals	GWP42003-P	—	COMPLETED	2018-09-11	NCT02607891
Aquestive Therapeutics	Diazepam Buccal Film 12.5 mg	—	COMPLETED	2018-07-25	NCT03179891
PhytoTech Therapeutics, Ltd.	PLT101	—	COMPLETED	2018-06-28	NCT02987114
UCB Biopharma S.P.R.L.	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2018-04-27	NCT03021018
Idorsia Pharmaceuticals Ltd.	ACT-709478 for oral use	—	COMPLETED	2018-04-25	NCT03239691
UCB Pharma	Lacosamide	Voltage-gated sodium channels	COMPLETED	2018-04-10	NCT01969851
Marinus Pharmaceuticals	Ganaxolone	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	COMPLETED	2018-01-16	NCT02358538
Jazz Pharmaceuticals	GWP42006	—	COMPLETED	2017-07	NCT02365610
Jazz Pharmaceuticals	GWP42003-P	—	COMPLETED	2017-06-07	NCT02564952
UCB Biopharma S.P.R.L.	UCB0942	—	COMPLETED	2017-02	NCT02495844
Pfizer	PF-06372865	—	COMPLETED	2017-01-10	NCT02564029
Jazz Pharmaceuticals	GWP42003-P 20 mg/kg/Day Dose	—	COMPLETED	2016-07-21	NCT02565108
Nova Pneuma Inc.	B=Inhaled Alprazolam 0.5 mg	—	COMPLETED	2016-07	NCT02351115
INSYS Therapeutics Inc	Cannabidiol Oral Solution	—	COMPLETED	2016-05-09	NCT02324673
Jazz Pharmaceuticals	GWP42006	—	COMPLETED	2015-10	NCT02369471
Jazz Pharmaceuticals	GWP42003-P 5 mg/kg/day Dose	—	COMPLETED	2015-03-09	NCT02091206
UCB Pharma	Lacosamide	Voltage-gated sodium channels	COMPLETED	2014-08	NCT00938431
SK Life Science, Inc.	YKP3089	—	COMPLETED	2013-06	NCT01397968
Eisai Inc.	Perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2013-06	NCT01161524
UCB Pharma	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2013-03	NCT00422422
Acorda Therapeutics	Diazepam	Benzodiazepine [EPC]	COMPLETED	2013-02	NCT01417078
Bial - Portela C S.A.	ESL Banana taste	—	COMPLETED	2012-12	NCT02021461
UCB BIOSCIENCES, Inc.	Lacosamide	Voltage-gated sodium channels	COMPLETED	2012-10	NCT01118962
Novartis	BGG492	—	COMPLETED	2012-07	NCT01338805
Supernus Pharmaceuticals, Inc.	TPM XR	—	COMPLETED	2012-06	NCT01284530
Bial - Portela C S.A.	Eslicarbazepine acetate (BIA 2-093)	—	COMPLETED	2012-03	NCT01527513
UCB Japan Co. Ltd.	Levetiracetam	SV2A	COMPLETED	2012-02	NCT01407523
Novartis	Investigational new drug, company code: BGG492	—	COMPLETED	2011-09	NCT01147003
UCB BIOSCIENCES, Inc.	Lacosamide	Voltage-gated sodium channels	COMPLETED	2011-08	NCT01118949
Vertex Pharmaceuticals Incorporated	VX-765	—	COMPLETED	2010-11	NCT01048255
Marinus Pharmaceuticals	ganaxolone	Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator [EPC]	COMPLETED	2010-10	NCT01002820
Novartis	BGG492	—	COMPLETED	2010-09	NCT00784212
Novartis	Investigational new drug, company code: BGG492	—	COMPLETED	2010-08	NCT00887861
UCB BIOSCIENCES, Inc.	Keppra XR	SV2A	COMPLETED	2010-03	NCT00961441
UCB Pharma SA	Levetiracetam	SV2A	COMPLETED	2010-03	NCT00505934
Takeda	Soticlestat	—	TERMINATED	2025-07-30	NCT03635073
AbbVie	CVL-865	—	TERMINATED	2024-12-05	NCT04686786
UCB Biopharma SRL	Lacosamide intravenous	—	TERMINATED	2024-08-06	NCT04519645
Neurocrine Biosciences	NBI-921352	—	TERMINATED	2024-03-11	NCT05493293
Cerebral Therapeutics LLC	—	—	TERMINATED	2024-03-01	NCT04153175
Cerebral Therapeutics LLC	Valproic Acid delivered to ICV	—	TERMINATED	2024-03-01	NCT04529954
Equilibre Biopharmaceuticals B.V.	EQU-001	—	TERMINATED	2023-07-01	NCT05473442
UCB Biopharma SRL	Padsevonil	—	TERMINATED	2020-12-11	NCT03370120
UCB Biopharma SRL	UCB0942	—	TERMINATED	2020-11-24	NCT02625090
Radius Pharmaceuticals, Inc.	Cannabidiol Oral Solution	—	TERMINATED	2019-06-24	NCT03355300
Eisai Inc.	E2082	—	TERMINATED	2019-06-18	NCT03686033
Radius Pharmaceuticals, Inc.	Cannabidiol Oral Solution	—	TERMINATED	2019-05-15	NCT03336242
Eisai Inc.	E2730	—	TERMINATED	2019-02-14	NCT03603639
Acorda Therapeutics	diazepam nasal spray	—	TERMINATED	2016-07	NCT02316847
Acorda Therapeutics	diazepam nasal spray	—	TERMINATED	2016-05	NCT02474407
UCB BIOSCIENCES, Inc.	Brivaracetam intravenous solution	—	TERMINATED	2014-10	NCT02088957
Vertex Pharmaceuticals Incorporated	VX-765 Part A	—	TERMINATED	2013-08	NCT01501383
GSK	ezogabine/retigabine	—	TERMINATED	2013-04-29	NCT01494584
Pfizer	ICA-105665	—	TERMINATED	2010-09	NCT00979004
Biohaven Therapeutics Ltd.	BHV-7000	—	ENROLLING BY INVITATION	2026-12	NCT06443463
Engrail Therapeutics INC	ENX-101	—	WITHDRAWN	2024-09	NCT05481905
MGC Pharmaceuticals d.o.o	MGCND00EP1	—	WITHDRAWN	2024-05-30	NCT04406948
ES Therapeutics Australia Pty Ltd	ES-481	—	WITHDRAWN	2021-10	NCT04737174
Novartis	BGG492	—	WITHDRAWN	2010-11	NCT01167335

Showing 52 of 52 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Suninflam Inc	SIF001	—	RECRUITING	2027-01-15	NCT07051629
Actio Biosciences, Inc.	ABS-1230	—	RECRUITING	2026-03	NCT07156201
iQure Australia Pty Ltd	iQ-007	—	ACTIVE NOT RECRUITING	2026-01-29	NCT06899230
Shanghai UniXell Biotechnology Co., Ltd	UX-GIP001	—	NOT YET RECRUITING	2029-07-01	NCT07572812
SK Life Science, Inc.	Xcopri	Sodium Channel Antagonists [MoA]	COMPLETED	2025-11-06	NCT04903314
NeuroPro Therapeutics, Inc.	NPT 2042 (Reference formula/Formulation 1)	—	COMPLETED	2025-11-04	NCT07222878
Biocodex	Stiripentol capsule (Diacomit®)	—	COMPLETED	2025-08-27	NCT07176832
NeuroPro Therapeutics, Inc.	NPT 2042	—	COMPLETED	2025-06-26	NCT06525649
Humanis Saglık Anonim Sirketi	Perampanel 10 MG	—	COMPLETED	2023-11-26	NCT06450236
Humanis Saglık Anonim Sirketi	Perampanel 12 MG	—	COMPLETED	2023-09-20	NCT06450223
NeuroPro Therapeutics, Inc.	NPT 2042 (bumetanide analog) or Matching Placebo	—	COMPLETED	2023-03-17	NCT05503511
UCB Biopharma SRL	Alprazolam	Benzodiazepine [EPC]	COMPLETED	2022-04-05	NCT04857307
Otsuka Pharmaceutical Development & Commercialization, Inc.	OPC-214870	—	COMPLETED	2021-10-11	NCT04241965
UCB Biopharma S.P.R.L.	Padsevonil	—	COMPLETED	2019-05-18	NCT03695094
Sanofi	sodium valproate	—	COMPLETED	2019-04-11	NCT03681158
Neurelis, Inc.	NRL-1	—	COMPLETED	2019-04-10	NCT02724423
Supernus Pharmaceuticals, Inc.	BIS-001 ER	—	COMPLETED	2017-09-30	NCT03156439
Bial - Portela C S.A.	Eslicarbazepine acetate (ESL)	—	COMPLETED	2017-01-05	NCT03116321
Takeda	TAK-935	—	COMPLETED	2016-04	NCT02539134
Takeda	TAK-935	—	COMPLETED	2015-12	NCT02497235
GSK	Lamotrigine Dispersible/Chewable tablet	—	COMPLETED	2014-07-08	NCT02064465
Bial - Portela C S.A.	BIA 9-1067	—	COMPLETED	2014-04	NCT02305329
Jazz Pharmaceuticals	GWP42006	—	COMPLETED	2013-12	NCT01918735
GSK	Lamotrigine Dispersible/Chewable tablets 5mg*5	—	COMPLETED	2013-06-06	NCT01879423
GSK	50mg Ezogabine/retigabine	—	COMPLETED	2012-06-27	NCT01462669
GSK	Retigabine / Ezogabine	—	COMPLETED	2012-04-24	NCT01480609
GSK	Digoxin Alone	—	COMPLETED	2012-04-17	NCT01583036
GSK	Topiramate coated tablet	—	COMPLETED	2011-09-11	NCT01439438
GSK	Investigational Medicinal Product (MR1)	—	COMPLETED	2011-05-23	NCT01332513
GSK	Lamotrigine	Anti-epileptic Agent [EPC]	COMPLETED	2011-05-23	NCT01357902
GSK	Gabapentin 300 mg	—	COMPLETED	2011-01-22	NCT01738893
Supernus Pharmaceuticals, Inc.	Topiramate IR	—	COMPLETED	2010-12	NCT01114854
Bial - Portela C S.A.	BIA 2-093	—	COMPLETED	2010-11	NCT02284880
Eisai Inc.	Perampanel and Microgynon-30	—	COMPLETED	2010-10	NCT01209858
Eisai Inc.	perampanel	Noncompetitive AMPA Glutamate Receptor Antagonist [EPC]	COMPLETED	2010-09	NCT01240187
Bial - Portela C S.A.	BIA 2-093	—	COMPLETED	2009-11	NCT02284854
Roxane Laboratories	Oxcarbazepine	Anti-epileptic Agent [EPC]	COMPLETED	2009-09	NCT01702623
Roxane Laboratories	Oxcarbazepine	Anti-epileptic Agent [EPC]	COMPLETED	2009-09	NCT01703468
Bial - Portela C S.A.	Eslicarbazepine acetate	Voltage-gated sodium channels	COMPLETED	2009-08	NCT00987558
UCB Pharma	Lacosamide	Voltage-gated sodium channels	COMPLETED	2009-02	NCT01450111
Bial - Portela C S.A.	Eslicarbazepine acetate	Voltage-gated sodium channels	COMPLETED	2008-12	NCT00900237
Bial - Portela C S.A.	eslicarbazepine acetate and Microginon®	—	COMPLETED	2008-11	NCT00898560
UCB Pharma	Brivaracetam	Epoxide Hydrolase Inhibitors [MoA]	COMPLETED	2008-10	NCT00736931
GSK	lamotrigine	Anti-epileptic Agent [EPC]	COMPLETED	2008-09-12	NCT00627575
GSK	Lamotrigine tablet	—	COMPLETED	2008-03-06	NCT00605371
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	paliperidone ER	—	COMPLETED	—	NCT01060228
Receptor Life Sciences	High dose RLS103	—	TERMINATED	2024-02-23	NCT05678881
H. Lundbeck A/S	Lu AG06466	—	TERMINATED	2022-04-14	NCT05081518
NeuroVista Corporation	—	—	TERMINATED	2012-08	NCT01043406
Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.	Brivaracetam Oral Solution (Test Formulation)	—	ENROLLING BY INVITATION	2024-12-31	NCT06762743
UCB Biopharma SRL	Padsevonil type 1 Tablet 200 mg	—	WITHDRAWN	2020-05-22	NCT04283136
GSK	Retigabine	—	WITHDRAWN	2012-10-18	NCT01691872

Novel Seizures Drugs by Company (New molecular entities)

2 companies have an FDA-approved novel drug for Seizures.

JAZZ PHARMS RES 1 drug

EPIDIOLEX

CANNABIDIOL

NDA 2018

IMMEDICA PHARMA 1 drug

ZTALMY

GANAXOLONE

NDA 2022

Reformulations (11 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.